CPSF7

Across TCGA pan-cancer cohorts, CPSF7 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CPSF7 data layer compared with 28 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CPSF7 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CPSF7 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

HNSC, PDAC, and LSCC are the cancer types where CPSF7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	All	0.815	0.930	.010	16	view →
PDAC	DFS	Median	IV	0.785	0.214	.006	9	view →
LSCC	DFS	Quartile	All	0.896	0.539	.006	7	view →
COAD	DFS	Median	All	1.000	0.921	.017	6	view →
LUAD	OS	Tertile	II,III,IV	1.000	0.445	.035	4	view →
GBM	DFS	Median	All	0.448	0.308	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CPSF7–HNSC (OS)

Open the HNSC breakdown →